| Zerbaxa (ceftolozane /tazobactam) / Merck (MSD) |
ACTRN12623000976684: Ceftolozane/Tazobactam Continuous Intravenous Infusion given in an Outpatient Setting to treat Infective Exacerbations of Cystic Fibrosis and Bronchiectasis |
|
|
| Not yet recruiting | 4 | 30 | | | Sunshine Coast Hospital and Health Service, Merck, Sharp & Dohme (Australia) Pty Ltd | Bronchiectasis, Cystic Fibrosis | | | | |
2021-003847-10: A study comparing a 7-day versus a 14-day course of antibiotics against an infection affecting the blood caused by a bacteria called Pseudomonas aeruginosa. Estudio en el que se compara un tratamiento con antibióticos de 7 dÃas frente a uno de 14 dÃas de duración contra una infección que afecta a la sangre producida por una bacteria llamada Pseudomonas aeruginosa. |
|
|
| Ongoing | 4 | 304 | Europe | Tablet, Solution for infusion, Powder for infusion, Powder for solution for infusion, Ciprofloxacin, Levofloxacin, Piperacillin/Tazobactam, Ceftazidime, Cefepime, Ceftazidime/Avibactam, Ceftolozane/Tazobactam, Imipenem, Meropenem, Meropenem-Vaborbactam, Colistin, Amikacin, Tobramycin, Aztreonam | Fundación Pública Andaluza para la Gestión de la Investigación en Salud de Sevilla (FISEVI), ICI21/00075 (ISCIII) | Adult patients with bloodstream infections produced by Pseudomonas aeruginosa. Pacientes adultos con bacteriemia producida por Pseudomonas aeruginosa., Adult patients with infections that produce the passing of Pseudomonas aeruginosa bacteria to the blood. Pacientes adultos con infecciones que producen el paso de bacterias de Pseudomonas aeruginosa a la sangre., Diseases [C] - Bacterial Infections and Mycoses [C01] | | | | |
2021-006908-32: Pulmonary beta-lactam levels in ICU pneumonia Niveles intra-pulmonares de betalactámicos en neumonías en UCI |
|
|
| Not yet recruiting | 4 | 28 | Europe | ceftazidima/avibactam, ceftolozano\tazobactam, EMA/369737/2020, Powder for concentrate for solution for infusion, ZAVICEFTA 2 G/0,5 G POLVO PARA CONCENTRADO PARA SOLUCION PARA PERFUSION, Zerbaxa 1 g/0,5 g polvo para concentrado para solución para perfusión | Sonia Luque Pardos, Instituto de Salud Carlos III | Nosocomial pneumonia Neumonía nosocomial, Nosocomial pneumonia Neumonía nosocomial, Diseases [C] - Bacterial Infections and Mycoses [C01] | | | | |
CERTAIN, NCT06035055: Ceftolozane/Tazobactam Continuous Infusion for Infective Exacerbations of Cystic Fibrosis and Bronchiectasis |
|
|
| Not yet recruiting | 4 | 30 | NA | Ceftolozane/tazobactam | Sunshine Coast Hospital and Health Service, The Prince Charles Hospital, Mater | Bronchiectasis, Cystic Fibrosis, Pseudomonas Aeruginosa, Burkholderia Cepacia Infection | 10/23 | 01/24 | | |
CEF-10, NCT05061654: CEFtolozane-Tazobactam for the Empiric Anti-bacterial Treatment of Neutropenic Fever in Hematology Patients |
|
|
| Withdrawn | 4 | 164 | RoW | Ceftolozane-tazobactam IV, Zerbaxa | Hamad Medical Corporation, Merck Sharp & Dohme LLC | Neutropenia, Febrile, Hematologic Cancer | 01/24 | 06/24 | | |
CLEMENT, NCT06342115: Ceftolozane/Tazobactam Versus Meropenem for Febrile Neutropenia on Patients Colonized With or at Risk for Infection With Extended Spectrum Beta Lactamase - Producing Pathogens |
|
|
| Not yet recruiting | 4 | 176 | RoW | Ceftolozane-Tazobactam, Meropenem | Beneficência Portuguesa de São Paulo, Merck Sharp & Dohme LLC | Febrile Neutropenia | 04/25 | 04/25 | | |
| Recruiting | 3 | 80 | Europe | 1 hour infusion, Zerbaxa 1 g/0.5 g powder, 4 hours infusion | University Hospital, Toulouse | Ventilator-associated Pneumonia | 02/25 | 02/25 | | |
2019-002327-15: Beta-lactam Intermittent versus Continuous infusion and Combination antibiotic therapy in Sepsis |
|
|
| Not yet recruiting | 3 | 600 | Europe | Ceftazidime, Piperacilline Tazobactam, Cefepime, Ceftazidime/Avibactam, Ceftolozane/Tazobactam, Meropenem, Amikacine, Powder for concentrate for solution for infusion, Powder for solution for injection, Powder for injection | APHP, Assistance Public - Hôpitaux de Paris | Beta-lactam Intermittent vs Continuous infusion and Combination antibiotic therapy in Sepsis Administration par perfusion intermittente versus continue de ß-lactamines et combinaison par bi-antibiothérapie dans le sepsis, Beta-lactam Intermittent vs Continuous infusion and Combination antibiotic therapy in Sepsis Administration par perfusion intermittente versus par perfusion continue de ß-lactamines et combinaison par bi-antibiothérapie dans le sepsis, Not possible to specify | | | | |
NCT04673175: Ceftolozane-Tazobactam for Directed Treatment of Pseudomonas Aeruginosa Bacteremia and Pneumonia in Patients With Hematological Malignancies and Hematopoietic Stem Cell Transplantation |
|
|
| Recruiting | 1/2 | 20 | US | Ceftolozane / Tazobactam Injection | Weill Medical College of Cornell University, Merck Sharp & Dohme LLC | Pseudomonas Aeruginosa, Pneumonia, Hematologic Malignancy | 12/25 | 12/25 | | |
NCT02725216 / 2014-003485-24: Pharmacokinetic and Safety Study of Ceftolozane/Tazobactam in Pediatric Participants Receiving Antibiotic Therapy for Proven or Suspected Gram-negative Infection or for Peri-operative Prophylaxis (MK-7625A-010) |
|
|
| Recruiting | 1 | 36 | US | ceftolozane/tazobactam | Merck Sharp & Dohme Corp., Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. | Proven or Suspected Gram-negative Bacterial Infection, Peri-operative Prophylaxis | 11/16 | 11/16 | | |
| Completed | 1 | 40 | Europe, US, RoW | Ceftolozane/Tazobactam, MK-7625A | Merck Sharp & Dohme LLC | Nosocomial Pneumonia | 09/24 | 09/24 | | |
GMC-9, NCT03963297: Multicenter Evaluation of the Susceptibility of Enterobacteriaceae and Pseudomonas Aeruginosa to Ceftolozane/Tazobactam Combination |
|
|
| Completed | N/A | 747 | Europe | | Groupe Hospitalier Paris Saint Joseph | Antibiotic Resistant Strain | 03/20 | 12/22 | | |
NCT04033029: Antibiotic Plasma Concentrations During Continuous Renal Replacement Therapy With a High Adsorption Membrane (oXiris®) |
|
|
| Completed | N/A | 20 | Europe | Continuous venovenous hemodiafiltration with high adsorption membrane (oXiris®), Antibiotics, Piperacillin/tazobactam, Ceftazidime, Cefepime, Daptomycin, Ceftolozane/tazobactam | Hospital Universitari de Bellvitge, Baxter Healthcare Corporation | Hemodiafiltration, Sepsis, Acute Kidney Injury | 06/23 | 06/23 | | |
NCT06422533: Ceftolozane/Tazobactam vs. Piperacillin/Tazobactam for the Treatment of Bacteremia in Hemato-oncological Patients |
|
|
| Recruiting | N/A | 226 | RoW | Ceftolozane/tazobactam, Zerbaxa, Piperacillin/tazobactam, Tazocin, Pipertazo, Tazonam, Tazovak | Instituto Nacional de Cancerologia de Mexico | Hematologic Neoplasms, Neutropenia | 07/25 | 08/25 | | |
| Recruiting | N/A | 200 | Europe | Collection of blood and bronchoalveolar samples to study Pharmacokinetics of ceftazidime/avibactam, meropenem/varbobactam, ceftolozane/tazobactam, or cefiderocol | Policlinico Hospital, Pfizer | Acute Respiratory Distress Syndrome, Nosocomial Infection, Extracorporeal Membrane Oxygenation Complication | 12/25 | 12/26 | | |
ChiCTR2300070223: An assessment of the Ceftolozane/Tazobactam and Imipenem/Relebactam activity in the hypervirulent Klebsiella pneumoniae |
|
|
| Not yet recruiting | N/A | 1000 | | none | Peking University Third Hospital; Peking University Third Hospital, self-financing | Infectious disease | | | | |
